Prostate Health Market Size, Share and Growth Analysis Report - Forecast Trends and Outlook 2026-2030

The prostate health market covers pharmaceuticals, diagnostics, and interventional products that address prostate cancer, BPH, prostatitis, and related disorders. With a 2025 valuation near USD 23.93 billion and a compound annual growth rate of approximately 7.5%, the market sits at the intersection of oncology and urology. Independent forecasts vary widely depending on whether they include only therapeutics or the full diagnostic and device stack, with reported 2025 sizes ranging from about USD 14 billion for BPH treatment alone to over USD 46 billion for the broader prostate health category.

• •Aggregated 2025 market value: approximately USD 23.93 billion across therapeutics, diagnostics, and devices.
• •Forecast CAGR is roughly 7.5%, with projections spanning 3% to 10% depending on scope.
• •Market growth closely tracks prostate cancer incidence and global demographic aging.

Rising life expectancy and the growing share of men over 50 are expanding the addressable patient pool for both BPH and prostate cancer. Improved screening uptake, particularly PSA testing and MRI-based diagnostics, is enabling earlier detection and longer treatment durations. The introduction of novel androgen receptor inhibitors, PARP inhibitors, and radioligand therapies is also lifting per-patient spending and expanding the therapeutic toolkit.

• •Aging populations in North America, Europe, and East Asia are increasing the prevalence of BPH and prostate cancer.
• •Adoption of next-generation hormonal agents and radioligand therapies is raising treatment values.
• •Greater health awareness and improved insurance coverage are expanding access to diagnostics in emerging markets.

By indication, the market is dominated by prostate cancer therapeutics and BPH treatments, with diagnostics forming a smaller but fast-growing segment. By product type, pharmaceuticals lead revenue, followed by surgical and minimally invasive devices such as laser systems, Rezum, and UroLift, alongside imaging and biomarker diagnostics. North America holds the largest share thanks to high screening rates and premium drug uptake, while Asia-Pacific is the fastest-growing region as China, Japan, and India expand cancer screening and urology infrastructure.

• •Prostate cancer and BPH together account for the majority of market revenue.
• •North America leads in market share; Asia-Pacific is the fastest-growing regional segment.
• •Minimally invasive BPH devices and advanced imaging diagnostics are the most rapidly expanding subcategories.

What are the recent trends and outlook?

Precision oncology is reshaping prostate cancer care through genomic testing, PARP inhibitors for BRCA-mutated disease, and PSMA-targeted radioligand therapies. In BPH, the shift from long-term medication toward office-based minimally invasive procedures is accelerating, supported by payer recognition of cost savings. Looking ahead, combination regimens, AI-assisted diagnostics, and expanded screening programs in Asia-Pacific are expected to sustain mid-to-high single-digit growth through the next decade.

• •PSMA-targeted radioligand therapy is emerging as a major growth frontier in prostate cancer.
• •Minimally invasive BPH procedures such as Rezum and UroLift are gaining share over chronic drug therapy.
• •AI-driven imaging and biomarker analytics are improving early detection and risk stratification.